Alnylam Pharmaceuticals Inc. and Genzyme, both of Cambridge, said Monday that they have formed an exclusive alliance to develop and commercialize RNAi therapeutics for the treatment of transthyretin-mediated amyloidosis, or ATTR, in Japan and other Asia-Pacific countries. Under the terms of the agreement that also includes development milestone payments and tiered royalties, Genzyme will make an upfront cash payment of $22.5 million to Alnylam. ATTR is a rare hereditary disease that damages the nervous system and heart, resulting in a life expectancy of five to 15 years.
Unlimited access to BostonGlobe.com for only 99 cents for the first 4 weeks.Sign up
Are you a home delivery subscriber?
Get FREE access as part of your print subscriptionStart Here
Contact us for help